Intuitive reported better-than-expected second-quarter revenues and announced plans to roll out a new extended use program for certain surgical instruments, but remains cautious for the second half amid the COVID-19 pandemic.
Intuitive Surgical, Inc.’s financial performance beat analysts’ expectations for the second quarter of 2020, driven by an intra-quarter recovery of system placements as well as procedure volume as the COVID-19 pandemic rages on.
But for Wells Fargo’s analyst Larry Biegelsen, the most important announcement during the call was the launch of the “Extended...
After receiving US FDA clearance and reporting first successful use at Mayo Clinic, the Silicon Valley start-up plans to partner with leading centers to transform needle-based procedures with its robotic system starting with urology, then expand into other specialties, the CEO said.
Microbot wins FDA nod for Liberty, Medtronic’s Hugo showed positive results in hernia repair in clinical studies, Obvius Robotics reports first human procedure with CERTA, Ronovo closes a $67m financing round with JJDC, and Quantum expands Epione CE marking to bone tumors.
The value proposition of surgical robots is quickly changing. Gone is the focus on benefit to patients; instead cost, operative efficiency and surgeon longevity are the new focal points, making deciphering M&A value much more difficult.
Medtronic beat first-quarter revenue and EPS estimates, raised guidance, and added two board members and special committees as Elliott takes a stake.
Medtech Insight spoke with Sanjay Kakkar, Tensive CEO, about the firm’s breast tissue regeneration implant and its surgical benefits, including a reduced operation time of 74 minutes. He anticipates regulatory approval for Regenera in early 2027.
After receiving US FDA clearance and reporting first successful use at Mayo Clinic, the Silicon Valley start-up plans to partner with leading centers to transform needle-based procedures with its robotic system starting with urology, then expand into other specialties, the CEO said.
SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.
